Covid-19 oral antiviral MK-4482 (molnupiravir)
Ended Definitive Contract Awarded Last action
- Contract number
- W911QY21C0031
- Awardee
-
Merck Sharp & Dohme LLC UEI FCFDA78HKKG2 Part of Schering Plough Corporation
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Obligated
- $2,205,000,834
Award facts
- Opportunity
-
- Program Announcement: JPEO-CBRND & BARDA Commercial Solutions Opening (CSO) Special Notice · W911QY20SC001 · Posted Jun 18, 2020
- Medical Countermeasures (MCM) Commercial Solutions Opening (CSO) Solicitation · Posted Jun 29, 2020
- Contract value 60% obligated
-
- $2,205,000,834.00 Current, with exercised options
- $3,700,200,834.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Kenilworth, NJ 07033, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $200,986 | |
| Exercise an Option | $996,800,000 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,207,999,848 |
About this award
This $3.7 billion firm fixed price contract was awarded by the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense (DOD - Army) to Merck Sharp & Dohme LLC for the manufacturing and fill-finish of a minimum of 100,000 treatment courses of the COVID-19 oral antiviral MK-4482 (molnupiravir). The contract is being performed by Merck in Kenilworth, New Jersey and will run from June 2021 through July 2023.
The solicitation was issued through the Commercial Solutions Opening (CSO) Area of Interest under the Joint Program Executive Office - Chemical Biological Radiological Nuclear Defense (JPEO-CBRND) and Biomedical Advanced Research and Development Authority (BARDA) to obtain proposals for the rapid manufacturing of a SARS-CoV-2 medical countermeasure therapeutic. Offerors were required to demonstrate capability to obtain Emergency Use Authorization or FDA approval by the end of 2020 and begin phase 3 clinical trials by fourth quarter 2020, consistent with the goals of this contract.
Quick answers
Who was awarded contract W911QY21C0031?
W911QY21C0031 was awarded to Merck Sharp & Dohme LLC by ACC Aberdeen Proving Ground (Army Contracting Command) on June 7, 2021.
How much is contract W911QY21C0031 worth?
The government has obligated $2,205,000,834 on W911QY21C0031. Its potential value, with all options, is $3,700,200,834.
Which agency awarded contract W911QY21C0031?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911QY21C0031, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Was contract W911QY21C0031 competed?
The extent of competition for W911QY21C0031 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award